Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | -9.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.42 | N/A | -9.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance metrics. They did not provide any updates on future guidance, indicating uncertainty.
Management acknowledged challenges in meeting EPS expectations.
No specific revenue guidance was provided for the upcoming quarters.
Nektar Therapeutics' earnings report shows a miss on EPS, which likely contributed to the stock's decline of 2.18%. The lack of revenue figures and guidance adds to investor uncertainty. Overall, the company's performance may raise concerns about its future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
JD COM INC Class A ADR
May 8, 2017